Interaction of therapy on bone mineral density in male and female patients with rheumatoid arthritis

October 2, 2019
589
Resume

Objective — to assess the effect of therapy on bone mineral density (BMD) in male and femail patients with rheumatoid arthritis (RA). Object and research methods. The study was performed on 145 RA patients aged 18–72 years: 117 (80.7%) women (mean age 45.4±13.0 years) and 28 (19.3%) men (mean age 46.4±16.9 years), who received mono- or combination therapy by methotrexate (MT), glucocorticoids (GC), and biological agents (BA). The study did not include patients used any other disease-modifying and osteotropic drugs. Patients were divided on groups, depending on received therapy. MT received 60.7% men, 87.0% women in reproductive (RP) and 85.4% — in postmenopausal period (PM); GK — 64.3% men, 62.3% women RP and 77.1% — PM; BA — 46.4 and 33.3%, respectively; male patients did not receive BA. Results. GC in women with RA significantly decrease BMD in all parts of skeleton, especially hip in women RP. MT treatment associated with decreased BMD on lumbar spine (LI–LIV) and total hip in women PM, BA protect bone mass (BM) lost on total hip and ultradistal part of forearm. GK on women RA is required to special attention for BM monitoring at total hip and ultradistal part of forearm. In men with RA, the site-specific dose-dependent GC effect is associated with standardization GC dose: ≥5 mg/day — with BMD LI–LIV spine and duration of GC administration on dose ≥5 mg/day — with BMD femur neck and middle part of forearm. The GC using in RA patients leads to systemic (reduction in BMD on different parts of the skeleton) and local (erosions and progression of the Ro-stage) loss of BM on male and femaile patients.

Published: 02.10.2019
References:

  • Vinogradova N.A. (2004) Vliyanie kombinirovannoy terapii glyukokortikosteroidami i metotreksatom na sustavnuyu destruktsiyu pri revmatoidnom artrite. Avtoref. dis. … kand. med. nauk. Moskva, 134.
  • Grigoreva N.V. (2009) Metotreksat i kostnaya tkan (obzor literaturyi). Nov. med. farmats., 19 (293) (http://www.mif-ua.com/archive/article/10567).
  • Blavnsfeldt A.G., de Thurah A., Thomsen M.D. et al. (2018) The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized, controlled trials. Bone, 114: 172–180.
  • Coulson K.A., Reed G., Gilliam B.E. et al. (2009) Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J. Clin. Rheumatol., 15: 155–160.
  • Cranney A.B., McKenedry R.J., Wells G.A. et al. (2001) The effect of low dose methotrexate on bone density. J. Rheumatol., 28: 2395–2399.
  • Di Munno O., Mazzantini M., Sinigaglia L. et al. (2004) Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J. Rheumatol., 31 (7): 1305–1309.
  • Heidari B., Firouzjahi A.R., Haj Mirghassemi M. et al. (2015) Relationship between bone mineral density and duration of rheumatoid arthritis. Ind. J. Rheumatol., 10: 10–15.
  • Heidari B., Hassanjani Roushan M.R. (2012) Rheumatoid arthritis and osteoporosis. Casp. J. Intern. Med., 3: 445–446.
  • Heidari B., Heidari P., Hajian-Tilaki K. et al. (2018) Effect of long-term low dose prednisolone administration on bone mineral density: relating to non-compliant women with rheumatoid arthritis. Casp. J. Intern. Med., 9 (2): 171–177.
  • Heidari B., Jalali F. (2005) Bone densitometry in patients with rherumatoid arthritis. Acta Med. Iran., 43: 99–104.
  • Schett G., Gravallese E. (2012) Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat. Rev. Rheumatol., 8: 656–664.
  • Shaw A.T., Gravallese E.M. (2016) Mediators of inflammation and bone remodeling in rheumatic disease. Semin. Cell Dev. Biol., 49: 2–10.